BIIB at a glance
Biogen (BIIB, SEC CIK 875045) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Biogen (BIIB) reported revenue of $9.9 billion (up 2.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $8.79.
- As of September 30, 2026, 43 institutional investment managers tracked by SignalX reported holding Biogen (BIIB) shares worth $13.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Minor Lloyd on August 4, 2026 of 593 shares at $200.96 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $9.9B
- +2.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 43 funds
- $13.0B · +0 vs prior quarter
- Latest 8-K
- Oct 28, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Global biopharmaceutical company developing and commercializing therapies primarily for neurology, specialized immunology, and rare diseases
- New or emphasized segment: Expanded collaboration with Genentech on multiple anti-CD20 therapies including recently approved GAZYVA for lupus nephritis in Oct 2025
- Strategic shift: Increased focus on biosimilars portfolio commercialization, including BENEPALI, IMRALDI, and FLIXABI as key growth drivers
- Quantitative highlight: Acquired in-process research and development expense surged to $471.8M in 2025 from $61.5M in 2024, signaling aggressive pipeline investment
- Noteworthy fact: Completed agreement to acquire Reata Pharmaceuticals (2023 filing) reflected in continued integration and intangible assets balancing $9.18B as of Dec 2025
Risk Factors
- Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty
- Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025
- Supply chain risk: TECFIDERA, VUMERITY, LEQEMBI raw materials and components partly sourced outside U.S., with tariffs and supplier substitution risks
- Competitive risk: TECFIDERA patent revoked by European Patent Office Nov 2025; multiple generic entrants causing significant revenue erosion
- Financial risk: $1.75 billion 2025 Senior Notes issuance with proceeds used to redeem $4.050% notes; $4.2 billion cash and equivalents end 2025
Management Discussion & Analysis
- No profitability or margin figures mentioned
- Capital investments include new biologics manufacturing facility in Solothurn, Switzerland; expansion supports LEQEMBI and TYSABRI production
- Future growth dependent on new product development, regulatory approvals, patent protection, and external business opportunities
AI summary of the BIIB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added international-trade risk: Section 232 Proclamation imposed 100% tariffs on certain pharmaceutical imports beginning July 31, 2026
- Most material product risk: TECFIDERA revenue fell 50.3% to $282.4 million after European patent revocation and generic entry
- Regulatory pricing risk: OBBBA implementation guidance remains pending, with most provisions effective in 2027 and 2028
- Operational risk: Apellis integration may delay expected benefits from EMPAVELI and SYFOVRE commercialization
- Financial risk: Cash and marketable securities declined to $1.3 billion while borrowings increased to $7.7 billion following Apellis acquisition
Management Discussion & Analysis
- Revenue $2,804.1M, up from $2,534.7M YoY, with product revenue $2,088.7M vs $1,846.9M
- Net loss $(20.6)M vs $466.5M income YoY, with net margin (0.7)% vs 18.4%
- Best product line SPINRAZA, $460.6M vs $374.0M; worst TECFIDERA, $82.0M vs $168.2M
- Operating cash flow $1,735.2M for nine months vs $1,692.7M; cash $1,303.9M vs $3,008.5M
- Apellis acquisition deployment $5,071.1M, with $2.0B term loan financing and $400.0M revolving-facility drawdown
AI summary of the BIIB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products
- Growth Portfolio revenue $1.26B, up 49%, now 63% of Core Pharmaceutical revenue
Item 2.02: Results of Operations and Financial Condition
- Biogen reported third-quarter fiscal 2026 results for the period ended September 30, 2026
- Full financial results and management commentary are contained in Exhibit 99.1, the accompanying press release
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for the quarter ended June 30, 2026 announced by Biogen
- Detailed financial results and operating metrics available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $2.736B, up 3% YoY, led by Growth Portfolio revenue of $1.06B, up 24%
- Non-GAAP EPS $3.60 versus $5.47, pressured by acquisition costs, pipeline investment, and Apellis financing expense
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 GAAP and non-GAAP EPS expected to include approximately $164 million of pre-tax milestone-related expense
- Q2 EPS impact estimated at approximately $0.95 per diluted share
AI summaries of BIIB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BIIB
Don't miss the next BIIB filing
- Alerts as it files. A push when BIIB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BIIB, by share count.
- Ask anything. An AI agent that reads every BIIB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Grogan Jane | F | Oct 30, 2026 | 345 | $253.62 |
| Grogan Jane | M | Oct 30, 2026 | 695 | - |
| Grogan Jane | M | Oct 30, 2026 | 695 | - |
| Godbout Sean | M | Oct 2, 2026 | 27 | - |
| Godbout Sean | F | Oct 2, 2026 | 8 | $219.88 |
| Godbout Sean | M | Oct 2, 2026 | 27 | - |
| Godbout Sean | A | Oct 1, 2026 | 985 | - |
| Parini Michael | A | Sep 1, 2026 | 7,405 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $9.8B | $9.7B | $9.9B |
| Net Income | $1.2B | $1.6B | $1.3B |
| Net Margin | 11.8% | 16.9% | 13.1% |
| Balance Sheet | |||
| Total Assets | $26.8B | $28.0B | $29.4B |
| Equity | $14.8B | $16.7B | $18.3B |
| ROE | 7.8% | 9.8% | 7.1% |
| Per Share | |||
| EPS | $7.97 | $11.18 | $8.79 |
| Cash Flow | |||
| Operating CF | $1.5B | $2.9B | $2.2B |
| CapEx | - | $153.7M | $153.8M |
Source: XBRL data in Biogen (BIIB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate BIIB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 43 | $13.05B |
| Q2 2026 | 43 | $16.09B |
| Q1 2026 | 40 | $12.48B |
| Q4 2025 | 39 | $11.75B |
| Q3 2025 | 41 | $8.65B |
| Q2 2025 | 38 | $7.43B |
| Q1 2025 | 37 | $6.15B |
| Q4 2024 | 36 | $5.77B |
- Citadel Advisors LLC+1.17M (+281%)
- State Street Corp+217.9K (+3%)
- JPMorgan Chase & Co+216.0K (+12%)
- Invesco Ltd+168.6K (+9%)
- BlackRock+103.5K (+1%)
- AQR Capital Management−426.1K (-22%)
- Goldman Sachs Group−297.4K (-24%)
- Renaissance Technologies LLC−76.3K (-98%)
- Franklin Resources−64.9K (-47%)
- Vanguard Portfolio Management LLC−32.8K (-0%)
- Millennium Management+242.1K
- Marex Group plc+10.6K
- FMR LLC (Fidelity)−18.22M
- Blackstone Group−2.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 317 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BIIB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 2, 2026 | - | - | - |
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | - | |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
BIIB SEC filings: frequently asked questions
Which institutions hold BIIB stock?
As of September 30, 2026, the largest Biogen (BIIB) holders among the 13F filers tracked by SignalX were BlackRock ($3.6 billion), Vanguard Capital Management LLC ($2.2 billion), State Street Corp ($1.7 billion), Vanguard Portfolio Management LLC ($1.5 billion), Morgan Stanley ($566.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BIIB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Biogen (BIIB) reported revenue of $9.9 billion (up 2.2% from FY2024) and net income of $1.3 billion. Diluted EPS was $8.79. The figures come from the XBRL data in the 10-K.
What are the main risks in BIIB's latest 10-K?
In the 10-K filed February 6, 2026, Biogen (BIIB) flagged: Regulatory risk: IRA Medicare Part D redesign caused $90 million 2025 revenue loss, impacting SKYCLARYS and MS portfolio with future pricing enforcement uncertainty. Geopolitical risk: Russia-Ukraine conflict may disrupt supply; revenues from Russia, Ukraine, Middle East each <2.0% of total revenue in 2023-2025. (AI summary of the Risk Factors section.)
What did BIIB report in its latest 8-K?
Biogen (BIIB) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $2.8B, up 11% year over year, signaling renewed growth led by the Growth Portfolio and Apellis products.
What are the latest BIIB SEC filings?
Biogen (BIIB) filed its latest 10-K annual report on February 6, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 2, 2026.
What is BIIB's SEC CIK number?
Biogen (BIIB)'s SEC Central Index Key (CIK) is 875045. EDGAR lists every BIIB filing under that number.
Ask anything about BIIB
The research agent reads BIIB's filings, financials, insider trades and 13F holders, then answers with sources.